Please assess the completion status of the following clinical trial:

Trial Title: Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent prior to initiation of any study mandated procedure.~2. Patients with symptomatic pulmonary arterial hypertension (PAH) in modified World Health Organization (WHO) functional class II to IV.~3. Patients with the following types of pulmonary arterial hypertension (PAH) belonging to groups 1.1 to 1.3 of the Venice classification:~   * Idiopathic (IPAH);~  * Familial (FPAH); or~  * Related to:~     * Collagen vascular disease;~    * Simple, congenital systemic-to-pulmonary shunts at least 1 year post surgical repair;~    * Human immunodeficiency virus (HIV) infection; or~    * Drugs and toxins.~4. PAH diagnosis confirmed by hemodynamic evaluation performed prior to randomization and showing all of the following:~   * Mean pulmonary artery pressure (mPAP) \> 25 mmHg at rest;~  * Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) \< 15 mmHg; and~  * Pulmonary vascular resistance (PVR) at rest \>= 320 dyn×sec/cm\^5.~5. 6-minute walk distance (6MWD) \>= 50 m.~6. Men or women \> 12 years of age (women of childbearing potential must have a negative pre-treatment serum pregnancy test and must use a reliable method of contraception).~Exclusion Criteria:~1. PAH associated with portal hypertension, thyroid disorders, glycogen storage disease, Gaucher''s disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders or splenectomy.~2. PAH associated with non corrected simple congenital systemic-to-pulmonary shunts, and combined and complex systemic-to-pulmonary shunts, corrected or non corrected.~3. PAH associated with significant venous or capillary involvement (PCWP \> 15 mmHg), known pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis.~4. Persistent pulmonary hypertension of the newborn.~5. Pulmonary Hypertension belonging to groups 2 to 5 of the Venice classification.~6. Moderate to severe obstructive lung disease: forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \< 70% and FEV1 \< 65% of predicted value after bronchodilator administration.~7. Moderate to severe restrictive lung disease: total lung capacity (TLC) \< 60% of predicted value.~8. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.~9. Estimated creatinine clearance \< 30 mL/min~10. Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 1.5 times the upper limit of normal.~11. Hemoglobin \< 75% of the lower limit of the normal range.~12. Systolic blood pressure \< 100 mmHg.~13. Acute or chronic physical impairment (other than dyspnea), limiting the ability to comply with study requirements.~14. Pregnant or breast-feeding.~15. Known concomitant life-threatening disease with a life expectancy \< 12 months.~16. Body weight \< 40 kg.~17. Any condition that prevents compliance with the protocol or adherence to therapy.~18. Recently started (\< 8 weeks prior to randomization) or planned cardio-pulmonary rehabilitation program based on exercise.~19. Treatment with endothelin receptor antagonists (ERAs) within 3 months prior to randomization.~20. Systemic treatment within 4 week prior to randomization with cyclosporine A or tacrolimus, everolimus, sirolimus (calcineurin or mammalian target of rapamycin (mTOR) inhibitors).~21. Treatment with cytochrome P3A (CYP3A) inducers within 4 weeks prior to randomization~22. Known hypersensitivity to drugs of the same class as the study drug, or any of their excipients.~23. Planned treatment, or treatment, with another investigational drug within 1 month prior to randomization.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Macitentan (ACT-064992) tablet, 3 mg, once daily
- 2 (Type: EXPERIMENTAL): Macitentan (ACT-064992) tablet, 10 mg, once daily
- 3 (Type: PLACEBO_COMPARATOR): Matching placebo, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete